Medpace (NASDAQ:MEDP) CFO Kevin Brady Sells 3,400 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) CFO Kevin Brady sold 3,400 shares of the business’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $625.24, for a total transaction of $2,125,816.00. Following the transaction, the chief financial officer owned 12,830 shares of the company’s stock, valued at approximately $8,021,829.20. The trade was a 20.95% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Medpace Price Performance

Medpace stock opened at $620.03 on Tuesday. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90. The stock has a market cap of $17.31 billion, a PE ratio of 36.34, a P/E/G ratio of 2.77 and a beta of 1.15. The stock’s fifty day moving average is $553.21 and its two-hundred day moving average is $492.40.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. During the same period in the previous year, the business earned $3.10 EPS. Medpace’s revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, research analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Medpace

Several hedge funds have recently made changes to their positions in MEDP. California State Teachers Retirement System lifted its holdings in shares of Medpace by 22.1% during the first quarter. California State Teachers Retirement System now owns 26,042 shares of the company’s stock worth $12,505,000 after purchasing an additional 4,719 shares during the period. Focus Partners Advisor Solutions LLC acquired a new position in Medpace in the 2nd quarter valued at $1,685,000. BlackRock Inc. purchased a new position in Medpace during the 2nd quarter worth $1,323,047,000. Cerity Partners LLC raised its position in Medpace by 41.0% during the 4th quarter. Cerity Partners LLC now owns 80,973 shares of the company’s stock worth $45,478,000 after buying an additional 23,530 shares during the last quarter. Finally, Local Pensions Partnership Investment Ltd lifted its stake in shares of Medpace by 10.5% in the 2nd quarter. Local Pensions Partnership Investment Ltd now owns 42,000 shares of the company’s stock worth $22,265,000 after acquiring an additional 4,000 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on MEDP shares. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and raised their price objective for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Robert W. Baird increased their target price on shares of Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. Barclays set a $600.00 price target on shares of Medpace in a research note on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $535.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Finally, Mizuho upped their price objective on shares of Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $584.18.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.